BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION Financial Statement Analysis
|
||
|
The Revenues of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION have decreased by -43.09% YoY .
The Earnings Per Share (EPS) of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION has decreased by Negative YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION Last 5 Annual Financial Results
[BOM: 524663]
| Standalone | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
|---|---|---|---|---|---|
| Revenues | ₹45 Cr | ₹78 Cr | ₹85 Cr | ₹67 Cr | ₹84 Cr |
| Expenses | ₹61 Cr | ₹83 Cr | ₹106 Cr | ₹77 Cr | ₹93 Cr |
| Operating Profit (Excl OI) | ₹-16 Cr | ₹-4.97 Cr | ₹-21 Cr | ₹-10 Cr | ₹-9.32 Cr |
| Other Income | ₹1.06 Cr | ₹1.10 Cr | ₹1.68 Cr | ₹1.18 Cr | ₹4.23 Cr |
| Interest | ₹7.06 Cr | ₹5.60 Cr | ₹4.79 Cr | ₹4.75 Cr | ₹2.00 Cr |
| Depreciation | ₹0.20 Cr | ₹0.21 Cr | ₹0.24 Cr | ₹0.24 Cr | ₹0.28 Cr |
| Profit Before Tax | ₹-22 Cr | ₹-9.69 Cr | ₹-24 Cr | ₹-14 Cr | ₹-7.37 Cr |
| Profit After Tax | ₹-17 Cr | ₹-8.75 Cr | ₹-18 Cr | ₹-10 Cr | ₹-5.79 Cr |
| Consolidated Net Profit | ₹-17 Cr | ₹-8.75 Cr | ₹-18 Cr | ₹-10 Cr | ₹-5.79 Cr |
| Earnings Per Share (Rs) | ₹-3.85 | ₹-2.03 | ₹-4.19 | ₹-2.36 | ₹-1.34 |
| PAT Margin (%) | -37.30 | -11.17 | -21.23 | -15.28 | -6.93 |
| ROE(%) | 0.00 | 0.00 | -158.64 | -39.93 | -17.00 |
| ROCE(%) | -25.63 | -8.08 | -73.05 | -21.87 | -10.70 |
| Total Debt/Equity(x) | -3.05 | -12.18 | 11.56 | 0.15 | 1.05 |
Key Financials |
||
| Market Cap | : | ₹ 142.1 Cr |
| Revenue (TTM) | : | ₹ 26.5 Cr |
| Net Profit(TTM) | : | ₹ -17.3 Cr |
| EPS (TTM) | : | ₹ -4.0 |
| P/E (TTM) | : | - |
| Industry Peers & Returns | 1W | 1M | 1Y |
| BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION | 10.8% | 20.7% | 34% |
| SUN PHARMACEUTICAL INDUSTRIES | -0.1% | -2.8% | 50.3% |
| CIPLA | 4.5% | -3.1% | 52.8% |
| DR REDDYS LABORATORIES | 4.6% | 1.4% | 22.2% |
| ZYDUS LIFESCIENCES | 3.1% | -4.1% | 80.4% |
| DIVIS LABORATORIES | 4.7% | 10.8% | 18.1% |
| MANKIND PHARMA | 2.7% | 12.4% | NA |
| TORRENT PHARMACEUTICALS | 6.1% | 5.3% | 66.2% |
| LUPIN | 3.1% | -1.1% | 127.4% |
BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION Revenues
[BOM: 524663]
| Y-o-Y | -43.09 % |
| 5 Yr CAGR | -14.54 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2023 | ₹45 Cr | -43.09 | |
| Mar2022 | ₹78 Cr | -8.14 | |
| Mar2021 | ₹85 Cr | 27.67 | |
| Mar2020 | ₹67 Cr | -20.10 | |
| Mar2019 | ₹84 Cr | - | |
BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION Operating Profit
[BOM: 524663]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2023 | ₹-16 Cr | Negative | |
| Mar2022 | ₹-4.97 Cr | Negative | |
| Mar2021 | ₹-21 Cr | Negative | |
| Mar2020 | ₹-10 Cr | Negative | |
| Mar2019 | ₹-9.32 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2023 | -36.02% | Negative | |
| Mar2022 | -6.35% | Negative | |
| Mar2021 | -24.45% | Negative | |
| Mar2020 | -15.56% | Negative | |
| Mar2019 | -11.14% | - | |
BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION Profit After Tax
[BOM: 524663]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2023 | ₹-17 Cr | Negative | |
| Mar2022 | ₹-8.75 Cr | Negative | |
| Mar2021 | ₹-18 Cr | Negative | |
| Mar2020 | ₹-10 Cr | Negative | |
| Mar2019 | ₹-5.79 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2023 | -37.3 % | Negative | |
| Mar2022 | -11.17 % | Negative | |
| Mar2021 | -21.23 % | Negative | |
| Mar2020 | -15.28 % | Negative | |
| Mar2019 | -6.93 % | - | |
BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION Earnings Per Share (EPS)
[BOM: 524663]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2023 | ₹-3.85 | Negative | |
| Mar2022 | ₹-2.03 | Negative | |
| Mar2021 | ₹-4.19 | Negative | |
| Mar2020 | ₹-2.36 | Negative | |
| Mar2019 | ₹-1.34 | - | |
BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION Return on Capital Employed (ROCE)
[BOM: 524663]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2023 | -25.63% | Negative | |
| Mar2022 | -8.08% | Negative | |
| Mar2021 | -73.05% | Negative | |
| Mar2020 | -21.87% | Negative | |
| Mar2019 | -10.7% | - | |
BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION Share Price vs Sensex
| Current Share Price | : | ₹32.9 |
| Current MarketCap | : | ₹ 142.1 Cr |
| Updated EOD on | : | Apr 25,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION | 10.8% |
20.7% |
34% |
| SENSEX | 1.3% |
2.6% |
24% |
BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION related INDICES
No BSE index found!
No NSE index found
You may also like the below Video Courses
FAQ about BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION Financials
How the annual revenues of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION have changed ?
The Revenues of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION have decreased by -43.09% YoY .
How the Earnings per Share (EPS) of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION have changed?
The Earnings Per Share (EPS) of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION has decreased by Negative YoY .
Check out Intrinsic Value of Peers of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION
Compare Stock Analytics of Peers of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
